On this page you can find out about studies we are currently delivering and upcoming studies that will be opening at our centre soon.
Study date: 09 January 2024
Status: Open
TRIUMPH-4 is a clinical research study for people with excess weight and knee osteoarthritis pain. The study will test how safe and well an investigational medicine (a medicine being studied) works for weight management and knee osteoarthritis pain.
If you would like further information, contact: PRCLeicester@uhl-tr.nhs.uk.
Study date: 21 December 2023
Status: Open
TRIUMPH-1 is a new clinical research study for people with excess weight. The study will test how safe and well an investigational medicine (a medicine being studied) works for weight management.
If you would like further information, contact: PRCLeicester@uhl-tr.nhs.uk.
Study date: 19 December 2023
Status: Open
The SYNCHRONIZE™-CVOT Trial is testing an investigational medication to see whether it is safe and if it has any effect on the heart, blood vessels, and/or body weight. We plan to enrol a wide variety of participants. This is because medications may affect people differently based on their age, sex, gender, and race/ethnicity
If you would like further information, contact: PRCLeicester@uhl-tr.nhs.uk.
Study date: 29 September 2023
Status: Open
This Pan-European pilot study compares Decentralised Clinical Trial (DCT) and hybrid approaches to conventional clinical trial approaches in patients with type 2 diabetes treated with a long-lasting insulin, called Toujeo®.
Study date: 14 September 2023
Status: Open
This study aims to find out if the treatment of type 1 diabetes is better with a new device called Omnipod® 5 compared to injections. The Omnipod® 5 is a tubeless insulin pump, also called a Pod, which delivers insulin constantly through a tiny plastic tube that sits under the skin. Pods are controlled by an app on a study-provided phone. It takes information from a blood sugar sensor called FreeStyle Libre 2 to adjust insulin delivery and keep your sugars in the healthy range.
If you would like further information, please contact: 0116 258 8575 or email: T1andTechResearch@uhl-tr.nhs.uk.
Study date: 14 July 2023
Status: Open
This study uses the FreeStyle Libre 3 Flash Continuous Glucose Monitoring System and is for people with type 2 diabetes who manage their blood sugar levels using long-acting, background insulin and other glucose-lowering medications, including drugs known as SGLT2 inhibitors or GLP-1RA. This study will help us to learn more about using continuous glucose monitoring systems in people with type 2 diabetes.
If you would like further information, please contact: 0116 258 8575 or email: freedm2@uhl-tr.nhs.uk.
Study date: 09 May 2023
Status: Open
The study, REDEFINE 3, is looking at a combination of two medicines. REDEFINE 3 is needed to help us understand how effective these two medicines are for reducing cardiovascular events, such as heart attacks and stroke. This study is funded and sponsored by Novo Nordisk.
This study is open at PRC: Bradford, PRC: Leicester, PRC: Exeter. And upcoming at PRC: Blackpool and PRC: Newcastle.
To find out more about the REDEFINE-3 study, please visit www.redefine3.org.uk or contact the team: prc@nihr.ac.uk.
Study date: 20 May 2021
Status: Open
Dapagliflozin is a commonly used medicine in diabetes care, it helps control blood sugar and promotes weight-loss. The DETA trial is investigating if this medicine also improves physical health, the ability to undertake daily activities, and whether its effects can be further improved when paired with an exercise programme.
There are currently no upcoming studies.
